Last updated on September 2018

Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab


Brief description of study

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.

Clinical Study Identifier: NCT03030183

Contact Investigators or Research Sites near you

Start Over

Investigative Site
Duarte, CA United States

Investigative Site
Los Angeles, CA United States

Investigative Site
Chicago, IL United States

Investigative Site
Manhasset, NY United States

Investigative Site
Durham, NC United States

Investigative Site
Dallas, TX United States